- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02110784
Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria
Proof of Concept Study of Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria
Study Overview
Detailed Description
Vivax malaria occurs throughout the tropical, subtropical and some of the temperate latitudes globally. During a primary infection some P. vivax parasites become dormant in the liver (hypnozoites) during large periods of time and might subsequently cause multiple blood-stage relapses.
The asexual stages of P. vivax are generally still sensitive to chloroquine (CQ) throughout most of the world with the exception of Indonesia and Papua New Guinea where high therapeutic failure rates ranging from 5-84% have been reported. Also, there are reports of chloroquine failure from other countries and regions where the species is endemic; in particular, the presence of CQ-resistant vivax strains is now well described in several countries, including India, Brazil, Peru and Colombia.
The treatment of the dormant stages and the prevention of relapses is reached throughout the 8-aminoquinolines (primaquine is the only commercially available in this indication).
The current treatments recommended by World Health Organization (WHO) for the radical cure of CQ-resistant vivax malaria are Artemisinin based Combination Therapies (ACTs) with partner drugs having very long half-life, combined with a two weeks regiment of primaquine (WHO, 2010).
Among a variety of suitable artemisinin-based combinations, the fixed combination of dihydroartemisinin (DHA) and piperaquine (PQP )is considered an excellent therapeutic approach since it has got all the requirements considered essential for showing a positive benefit/risk ratio in malaria therapy.
Sigma-Tau i.f.r. S.p.A. has developed a DHA+PQP formulation (Eurartesim®) manufactured according to international Good Manufacturing Practice (GMP) standards and has recently received marketing authorization in Europe via a centralized procedure by the European Medicine Agency (EMA) for uncomplicated episodes of P. falciparum malaria.
A substantial amount of data have been collected in patients with uncomplicated P. falciparum malaria treated with the DHA+PQP combination. In addition, several studies have provided evidence of high cure rate in patients with P. vivax malaria treated with DHA+PQP, however, no data are available so far on efficacy and safety of the DHA+PQP treatment in patients with imported P. vivax malaria. Acquiring data is therefore of particular importance since malaria represents an important burden among all travel-acquired illnesses considering not only the number of cases (10-20% of the imported malaria cases are due to P. vivax infection) but also the potential of a fatal outcome.
The aim of the present study is to investigate the efficacy, safety and tolerability of a therapeutic course of Eurartesim® in travellers who contracted malaria due to infection by P. vivax in endemic countries. The results of such "proof of concept" study will be used for estimating the failure rate in a precise way and to dimension one or more subsequent phase III trials of comparative efficacy.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Bordeaux Cedex, France
- Hôpital St André-CHU, Médecine interne et Maladies tropicales
-
-
-
-
-
Berlin, Germany
- Medizinische Klinik mit Schwerpunkt Infektiologie, Charite/Campus Virchow-Klinikum
-
Munich, Germany
- Department of Infectious Diseases & Tropical Medicine, University of Munich
-
-
-
-
-
Tel Hashomer, Israel
- 15. The Center for Geographic Medicine and Tropical Diseases, Department of Medicine C - The Chaim Sheba Medical Center
-
-
-
-
-
Brescia, Italy
- Clinica di Malattie Infettive e Tropicali, Universitá di Brescia
-
Milano, Italy, 20157
- Azienda Ospedaliera Luigi Sacco
-
Reggio Emilia, Italy, 42123
- Azienda Ospedaliera Arcispedale S. Maria Nuova IRCCS - Dip. Medicina Interna e Spec. Mediche
-
Roma, Italy
- Centro di Malattie Tropicali - INMI Spallanzani
-
-
-
-
-
Leiden, Netherlands
- Dep. Infectious Disease, Section Travel Medicine, Leiden University Medical Centre
-
-
-
-
-
Barcelona, Spain
- CRESIB-Hospital Clinic, Barcelona
-
Barcelona, Spain
- Hospital Vall D'Hebrón, Barcelona
-
-
-
-
-
Basel, Switzerland
- Medical and Diagnostic Service Department, Swiss Tropical and Public Health Institute
-
Bern, Switzerland
- Bern university hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Have read the Information for the Patient and signed the Informed Consent Form;
- Aged ≥18 years and able to swallow oral medication;
- Body weight comprised between 24 kg and 100 kg (included) for males and females;
- Uncomplicated malaria with microscopically confirmed monoinfection by Plasmodium vivax or mixed infection (i.e. infection with P. vivax and other Plasmodium species);
- Willingness to comply with the study protocol and the study visit schedule.
Exclusion Criteria:
- Participation in any investigational drug study during the previous 30 days;
- Antimalarial treatment with chloroquine and quinine within the previous 6 weeks, with piperaquine-based compounds or mefloquine or lumefantrine within the previous 3 months and with halofantrine within the previous 30 days prior to screening;
- P. vivax/Plasmodium species asexual stage parasitaemia ≥ 5% Red Blood Cells (in cases of mixed infection);
- Clinical and/or laboratory features of severe malaria according to WHO criteria (WHO 2010);
- ECG abnormality that requires urgent management (i.e. clinically significant arrhythmias, Atrio-Ventricular block II and III degree etc.);
- Family history of sudden death, or known congenital prolongation of the QT interval
- Lengthening of QT interval on ECG: corrected QT interval (Fridericia's correction) ≥450 ms for males and ≥470 ms for females;
- Concomitant administration of any treatment which can induce a lengthening of QT interval (i.e. antihistamines, macrolides, etc.) and of any antimalarial drugs (for the full list of prohibited drugs refer to section 8.3);
- Any contraindication to blood sampling (i.e. important haemorrhagic diathesis);;
- Presence of intercurrent illness or any condition (i.e. severe vomiting and dehydration) which in the judgement of the Investigator would place the patient at undue risk or interfere with the study results;
- Hypoglycaemia (blood glucose levels < 2.2 mmol/L or < 40 mg/dL);
- Splenectomy;
- Pregnant or lactating women. During the study period (Day 0- Day 42), fertile women who are sexually active must use an adequate birth control method. They should utilize oral or patch contraceptives, contraceptive implant or depot injection or an intrauterine device from at least one month before screening and during the whole study period. In all the other cases they have to agree to remain inactive or use condoms with a spermicidal agent during the study period;
- Presence of jaundice;
- Known renal impairment (serum creatinine > 2X the upper limit of the hospital laboratory reference range);
- Known liver insufficiency (AST and/or ALT > 3X the upper limit of the hospital laboratory reference range);
- Relevant anaemia (Hb< 8 g/dL).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Eurartesim tablets
Eurartesim 320 mg piperaquine / 40 mg dihydroartemisinin film coated tablets.
one or more tablets according to the body weight, once a day dor three consecutive days.
|
dosage bands: 24 to <36 kg body weight: 2 tablets a day for three consecutive days 36 to <75 kg body weight: 3 tablets a day for three consecutive days 75 to 100 kg body weight: 4 tablets a day for three consecutive days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Uncorrected adequate clinical and parasitological response (ACPR)
Time Frame: 21 days after the start of treatment
|
The uncorrected ACPR will be considered met for all those patients that are not presenting parasitaemia and fever at day 21 follow-up visit.
|
21 days after the start of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of aparasitaemic patients
Time Frame: at day 1, 2, 3, 7, 21, 42
|
to evaluate efficacy of the treatment to clear blood from parasites
|
at day 1, 2, 3, 7, 21, 42
|
Proportion of afebrile patients
Time Frame: at day 1, 2, 3, 7, 21, 42
|
to evaluate the efficacy of eurartesim in reducing fever caused by malaria
|
at day 1, 2, 3, 7, 21, 42
|
uncorrected ACPR
Time Frame: at day 42
|
at day 42
|
|
Number of Patients with Serious and Non-Serious Adverse Events
Time Frame: up to 42 days from starting of treatment
|
up to 42 days from starting of treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Christoph Hatz, Prof Dr Med, Medical and Diagnostic Service Department, Swiss Tropical and Public Health Institute, Basel - Switzerland
Publications and helpful links
General Publications
- Hasugian AR, Purba HL, Kenangalem E, Wuwung RM, Ebsworth EP, Maristela R, Penttinen PM, Laihad F, Anstey NM, Tjitra E, Price RN. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis. 2007 Apr 15;44(8):1067-74. doi: 10.1086/512677. Epub 2007 Mar 5.
- Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet. 2007 Mar 3;369(9563):757-765. doi: 10.1016/S0140-6736(07)60160-3.
- Sinclair D, Gogtay N, Brand F, Olliaro P. Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria. Cochrane Database Syst Rev. 2011 Jul 6;(7):CD008492. doi: 10.1002/14651858.CD008492.pub2.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ST3073-ST3074-DM13-001
- 2013-003763-56 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria, Vivax
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
University of OxfordMenzies School of Health ResearchCompletedUncomplicated Vivax MalariaAfghanistan, Ethiopia, Indonesia, Vietnam
-
Centers for Disease Control and PreventionTerminated
-
Menzies School of Health ResearchMinistry of Health, MalaysiaUnknownPlasmodium Vivax Malaria Without ComplicationMalaysia
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
Menzies School of Health ResearchAga Khan University; University of Melbourne; Universitas Sumatera Utara; Ethiopian... and other collaboratorsRecruitingVivax Malaria | Malaria, Vivax | Plasmodium Vivax | Malaria RelapseCambodia, Ethiopia, Indonesia, Pakistan
-
Menzies School of Health ResearchUniversity of Melbourne; Curtin University; Addis Ababa University; Fundação de... and other collaboratorsNot yet recruitingVivax MalariaBrazil, Ethiopia, Indonesia, Papua New Guinea
-
University of OxfordCompleted
-
London School of Hygiene and Tropical MedicineHealthNet TPOCompletedMalaria | Vivax MalariaPakistan
Clinical Trials on Eurartesim tablets
-
sigma-tau i.f.r. S.p.A.CPR Pharma Services Pty Ltd, AustraliaCompletedMalaria, FalciparumAustralia
-
sigma-tau i.f.r. S.p.A.CPR Pharma Services Pty Ltd, AustraliaCompletedMalaria, FalciparumAustralia
-
PATHTulane University; Ministry of Health, Zambia; Minister of Community Development...CompletedMalaria | Malaria, FalciparumZambia
-
sigma-tau i.f.r. S.p.A.CompletedMalaria,FalciparumBurkina Faso, Congo, The Democratic Republic of the, Gambia, Mozambique, Tanzania
-
Liverpool School of Tropical MedicineThe Research Council of Norway; Makerere University; Kenya Medical Research InstituteCompleted
-
Simon KariukiCenters for Disease Control and PreventionCompleted
-
Chengdu Kanghong Pharmaceutical Group Co., Ltd.Recruiting
-
Centre of Clinical Pharmacology, Hanoi Medical...Not yet recruitingIrritable Bowel Syndrome With DiarrheaVietnam
-
Centro de Investigação em Saúde de ManhiçaBarcelona Institute for Global HealthCompleted
-
Lihir Medical CentreBarcelona Institute for Global Health; Papua New Guinea Institute of Medical... and other collaboratorsCompleted